

ASTRAZENECA PLC
Form 6-K
December 01, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of December 2016

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____

AstraZeneca PLC

INDEX TO EXHIBITS

1. Block listing Interim Review dated 01st December 2016

1 December 2016 16:00

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an ris.

Date: 1 DECEMBER 2016

Name of applicant: ASTRAZENECA PLC

Name of scheme: ASTRAZENECA SHARE OPTION PLAN;
ASTRAZENECA SAVINGS-RELATED
SHARE OPTION PLAN; ASTRAZENECA
ALL-EMPLOYEE SHARE PLAN;
ASTRAZENECA PLC 2012
SAVINGS-RELATED SHARE OPTION
SCHEME

Period of return: From: 31 MAY 2016 To: 30 NOVEMBER 2016

Balance of unallotted
securities under
scheme(s) from previous
return: 4,065,743

Plus: The amount by
which the block
scheme(s) has been
increased since the date 0
of the last return (if any
increase has been
applied for):

Less: Number of
securities issued/allotted
under scheme(s) during 478,408
period (see LR3.5.7G):

Equals: Balance under
scheme(s) not yet
issued/allotted at end of 3,587,335
period:

Name of contact: MARTIN BENNETT

Telephone number of contact: 07825 530066

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas -

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

Media Enquiries

| | | |
|------------------|-----------|------------------|
| Neil Burrows | UK/Global | +44 203 749 5637 |
| Vanessa Rhodes | UK/Global | +44 203 749 5736 |
| Karen Birmingham | UK/Global | +44 203 749 5634 |
| Rob Skelding | UK/Global | +44 203 749 5821 |
| Jacob Lund | Sweden | +46 8 553 260 20 |
| Michele Meixell | US | +1 302 885 2677 |

Investor Relations

| | | |
|---------------------|--|------------------|
| Thomas Kudsk Larsen | | +44 203 749 5712 |
| Craig Marks | Finance, Fixed Income, M&A | +44 7881 615 764 |
| Henry Wheeler | Oncology | +44 203 749 5797 |
| Mitchell Chan | Oncology | +1 240 477 3771 |
| Lindsey Trickett | Cardiovascular & Metabolic Diseases | +1 240 543 7970 |
| Nick Stone | Respiratory | +44 203 749 5716 |
| Christer Gruvris | Autoimmunity, neuroscience & infection | +44 203 749 5711 |
| US toll free | | +1 866 381 7277 |

Adrian Kemp
Company Secretary, AstraZeneca PLC
-ENDS-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Edgar Filing: ASTRAZENECA PLC - Form 6-K

Date: 01 December 2016 By: /s/ Adrian Kemp
Name: Adrian Kemp
Title: Company Secretary